FormidableMD vs Vaylen
Two GLP-1 desks, one scoreboard. We put FormidableMD and Vaylen head-to-head on the published Brief Score — the same six factors, scored the same way.
Vaylen
The verdict
Vaylen takes this head-to-head.
Vaylen scores 87 to 71 on our six-factor Brief Score — A full-service, LegitScript-certified desk pairing brand access and an oral route with nationwide reach at a fair mid price.
That doesn't make FormidableMD a bad call — it's best for readers who want florida patients wanting transparent, dose-based glp-1 pricing with no membership and pay-per-visit care. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| FormidableMD | Vaylen | |
|---|---|---|
| Brief Score | 71/100 (C) | 87/100 (B+) |
| Semaglutide | From $169/mo (1 mg dose, compounded) | $179/mo |
| Tirzepatide | From $199/mo (10 mg dose, compounded) | $239/mo |
| Coverage | 1 states | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
| On the tracker | Newnew to the tracker, no prior reading | Stableprice stable |
FormidableMD: New to the tracker on 1 August 2026. The published line reads From $169/mo (1 mg dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
Vaylen: $179 sema / $239 tirz; brand + oral + LegitScript across all 50 states.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.